Login / Signup

Inherited ARPC5 mutations cause an actinopathy impairing cell motility and disrupting cytokine signaling.

Cristiane J Nunes-SantosHye Sun KuehnBrigette BoastSuJin HwangDouglas B KuhnsJennifer StoddardJulie E NiemelaDanielle L FinkStefania PittalugaMones Abu-AsabJohn S DaviesValarie A BarrTomoki KawaiOttavia M DelmonteMarita BosticardoMary GarofaloMagda Carneiro-SampaioRaz SomechMohammad GharagozlouNima ParvanehLawrence E SamelsonThomas A FleisherAnne PuelLuigi Daniele NotarangeloBertrand BoissonJean-Laurent CasanovaBeata DerfalviSergio D Rosenzweig
Published in: Nature communications (2023)
We describe the first cases of germline biallelic null mutations in ARPC5, part of the Arp2/3 actin nucleator complex, in two unrelated patients presenting with recurrent and severe infections, early-onset autoimmunity, inflammation, and dysmorphisms. This defect compromises multiple cell lineages and functions, and when protein expression is reestablished in-vitro, the Arp2/3 complex conformation and functions are rescued. As part of the pathophysiological evaluation, we also show that interleukin (IL)-6 signaling is distinctively impacted in this syndrome. Disruption of IL-6 classical but not trans-signaling highlights their differential roles in the disease and offers perspectives for therapeutic molecular targets.
Keyphrases
  • early onset
  • single cell
  • late onset
  • cell therapy
  • oxidative stress
  • escherichia coli
  • cystic fibrosis
  • dna repair
  • biofilm formation
  • single molecule